The system, which has received CE Mark approval in Europe, adds to an increasingly crowded field of PFA technologies.

AI outperformed clinicians and almost matched hs-TnT testing, but one expert questioned if this is where it’s needed most.

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

The “passive” notification led to more patients with severe AS undergoing valve replacement, but more can be done still.

Disappointment over a cardiology board, an FDA approval, meeting news, and advice for practice—it’s all here this month.

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

While inconsistent dosing could have played a role, it still may be possible to identify the patients most likely to see ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

The recommendations are similar to those recently announced for TTVR, with the final NCD for T-TEER expected by July.

Experts are dismayed, disappointed, and confused, but many say this isn’t the end of cerebral embolic protection for TAVI.

Cotemporary DES paired with FFR guidance and modern medical therapy may be what narrowed the gap, William Fearon says.

The prothrombin complex concentrate costs more than plasma, but may pay dividends by way of fewer adverse events.